用司美格鲁肽减重后停药，44%的人都后悔了！

Core Viewpoint - China has the highest number of overweight and obese individuals globally, with over half of the adult population affected, leading to significant health concerns and potential market opportunities for weight loss solutions [1][2]. Group 1: Obesity Statistics - As of 2021, 16.4% of adults in China are classified as obese, while 34.3% are overweight, totaling approximately 532 million individuals, with nearly 100 million being obese [1]. - A 2020 study predicts that by 2030, the number of overweight adults in China will reach 540 million, and the obese population will increase to 150 million, representing growth of 2.8 times and 7.5 times, respectively, since 2000 [1]. Group 2: Medication Usage and Compliance - Semaglutide, a GLP-1 receptor agonist, has transformed the weight loss market, but many users discontinue its use after a period [2]. - Research indicates that 44% of patients remain on semaglutide after three months, 33% after six months, and only 19% after one year. In contrast, 63%, 56%, and 40% of semaglutide users continue after three months, six months, and one year, respectively [4]. Group 3: Effects of Discontinuation - A clinical trial showed that participants lost an average of 10.6% of their body weight during 20 weeks of semaglutide treatment, but those who switched to a placebo regained an average of 6.9% of their weight, while those who continued with semaglutide lost an additional 7.9% [5]. - An observational study found that 18% of patients regained their lost weight after one year off semaglutide, with 26% regaining more than 25% of their lost weight, while 56% maintained or continued to lose weight [5]. Group 4: Reasons for Discontinuation - Common side effects of GLP-1RA drugs include nausea, diarrhea, and vomiting, which may lead to discontinuation. Even at low doses, 17% of patients reported nausea, with higher rates of gastrointestinal issues at increased doses [6]. - Supply issues have also contributed to discontinuation, as semaglutide has been in short supply since 2022 [7]. - Other reasons for stopping include reaching a weight loss plateau or achieving target weight [9][10]. Group 5: Recommendations for Discontinuation - Gradual dose reduction is recommended to minimize rebound hunger and maintain weight loss. Patients should monitor their appetite and weight closely after discontinuation [11][14]. - Maintaining a healthy lifestyle post-medication is crucial to prevent weight regain, as obesity is a chronic condition requiring ongoing management [22]. Group 6: Lifestyle Management - The latest Chinese weight loss guidelines emphasize lifestyle interventions, including dietary management, exercise, and behavioral changes, as essential for long-term weight management [15]. - Dietary management aims to reduce caloric intake while improving metabolic health, with various dietary patterns showing short-term weight loss effects [16][18]. - Exercise plays a significant role in maintaining weight loss and improving quality of life, despite only achieving modest weight reductions on its own [19]. - Behavioral management is critical for successful weight loss, with structured programs showing significant weight reduction in the initial months [20][21].